Patents by Inventor Jens Jacob Hansen

Jens Jacob Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20180179262
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Hjortnaes Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Factor VIII Molecules with Reduced VWF Binding
    Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20160318991
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20160207977
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 10, 2014
    Publication date: July 21, 2016
    Inventors: Ole Hvilsted Olsen, Marianne Hjortnaes Kjalke, Maj Petersen, Lars Thim, Kirstine Roepstorff, Jens Jacob Hansen, Jesper Haaning, Frederik Rode, Ditte Maria Karpf, Christian Rischel, Gert Bolt
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20150376262
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Olsen, Jens Jacob Hansen
  • Compounds suitable for treatment of haemophilia
    Patent number: 9125890
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 8, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA
    Publication number: 20140018297
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 16, 2014
    Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20130040888
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: February 2, 2011
    Publication date: February 14, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen
  • Production of Bispecific Antibodies
    Publication number: 20090182127
    Abstract: Bispecific antibodies comprising (a) a first light-heavy chain pair having specificity for a first target and a sufficient number of substitutions in its heavy chain constant domain with respect to a corresponding wild-type antibody of the same isotype to significantly reduce the formation of first heavy chain-first heavy chain dimers and (b) a second light-heavy chain pair comprising a heavy chain having a sequence that is complementary to the sequence of the first pair heavy chain sequence with respect to the formation of intramolecular ionic interactions, wherein the first pair or second pair comprises a substitution in the light chain and complementary substitution in the heavy chain that reduces the ability of the light chain to interact with the heavy chain of the other light chain-heavy chain pair are provided. Methods of producing such antibodies in one or more cells also are provided.
    Type: Application
    Filed: June 22, 2007
    Publication date: July 16, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Jens Jacob Hansen, Soren Berg Padkaer